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AbstrACt
Introduction Needle-related procedures are considered 
as the most important source of pain and distress in 
children in hospital settings. Considering the physiological 
and psychological consequences that could result from 
these procedures, management of pain and distress 
through pharmacological and non-pharmacological 
methods is essential. Therefore, it is important to have 
interventions that are rapid, easy-to-use and likely to 
be translated into clinical practice for routine use. The 
aim of this study will be to determine whether a device 
combining cold and vibration (Buzzy) is non-inferior to a 
topical anaesthetic (liposomal lidocaine 4% cream) for 
pain management of children undergoing needle-related 
procedures in the emergency department.
Methods and analysis This study will be a randomised 
controlled non-inferiority trial comparing the Buzzy device 
to liposomal lidocaine 4% cream for needle-related pain 
management. A total of 346 participants will be randomly 
assigned in a 1:1 ratio to one of the two study groups. The 
primary outcome will be the mean difference in pain intensity 
between groups during needle-related procedures. A non-
inferiority margin of 0.70 on the Color Analogue Scale will 
be considered. A Non-inferiority margin of 0.70 on the Color 
Analogue Scale will be considered. The secondary outcomes 
will be the level of distress during the procedure, the success 
of the procedure at first attempt, the occurrence of adverse 
events, the satisfaction of both interventions and the memory 
of pain 24 hours after the procedure. The primary outcome will 
be assessed for non-inferiority and the secondary outcomes 
for superiority.
Ethics and dissemination This study protocol was reviewed 
and approved by the institutional review board of the study 
setting. Findings of this trial will be disseminated via peer-
reviewed publications and conference presentations.
trial registration number NCT02616419.
IntroduCtIon 
background and rationale
Needle-related procedures, such as venipunc-
tures and intravenous catheter insertions, 
are considered as the most important source 
of pain and distress in children in hospital 
settings.1–4 The intensity of pain and distress 
caused by these procedures can vary from 
mild to moderate for some, while for others, 
it may be severe.4–7 It is now recognised that 
even a such minor procedure, can result in 
numerous physiological, psychological and 
emotional consequences.8 9 Among these, 
needle phobia is the most important and prev-
alent one with more than 60% of children 
reporting an extreme fear of needles following 
a bad needle experience.10 These children 
are more likely to report higher levels of pain 
and distress from subsequent procedures,11 12 
and they can experience physiological symp-
toms, such as vasovagal reactions and an 
increased heart rate and blood pressure.13 14 
Furthermore, they can also develop health-
care avoidance behaviours in adulthood, such 
as delays in care, non-compliance of immuni-
sation requirements and avoidance of treat-
ment.10 14 Consequently, nurses play a critical 
role in the assessment and management of 
strengths and limitations of this study
 ► This is the first study to assess the efficacy of the 
Buzzy device in Canada.
 ► The large sample size of 346 participants will pro-
vide enough power to demonstrate the non-inferi-
ority of the Buzzy device compared with a topical 
anaesthetic.
 ► The non-inferiority margin is justified on both clinical 
and statistical grounds.
 ► This study presents potential clinical implications 
for nursing and medical practices in the emergency 
department.
 ► The main limitation of this trial is the impossibility 
to blind participants and personnel to intervention 
allocation.
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children’s pain and distress, and the use of pharmacolog-
ical and non-pharmacological interventions must be an 
integrant part of nursing practice.15 
Procedural pain management represents a major chal-
lenge for nurses, specifically for those working in the 
emergency department (ED). Consequently, children 
are at high risk for undertreatment of their pain during 
needle-related procedures.16 Although healthcare profes-
sionals recognise the importance of providing adequate 
procedural pain management, it is still suboptimal.8 17–19 
Several studies have identified different barriers to using 
available pharmacological and non-pharmacological 
interventions for pain management in the ED.8 17–19 
Barriers most frequently identified by nurses are time 
constraints, heavy workload, staffing limitations, space 
limitations, lack of knowledge and interruptions in the 
continuity of care.15 20–22
Currently, the gold standard intervention for needle-re-
lated procedural pain is the application of a topical anaes-
thetic prior to the procedure and several systematic reviews 
and meta-analysis have demonstrated its efficacy.23–26 
However, topical anaesthetics require an application time 
ranging from 30 min to 60 min, making their implementa-
tion for routine use difficult in the rapid and busy setting 
of the ED.27 28 Indeed, a study led by Papa and Zempsky27 
showed that only 28% of ED nurses used a topical anaes-
thetic during painful procedures they reported that main 
barriers to using it were the onset of action of the drug, 
treatment delays caused by application time and the 
vasoconstriction of blood vessels.27 Consequently, topical 
anaesthetics do not seem to be an optimal intervention 
for procedural pain management in an acute care setting 
where time constraints represent an important challenge 
to adequate pain control.21 29 In addition, they had a 
minimal side effect profile, including minor local reac-
tions, such as mild irritation, redness, itching, oedema or 
rash of the skin site following the application in 25%–50% 
of cases.24 25 29–31
Other pharmacological and non-pharmacological 
interventions have also been evaluated for their efficacy 
on children’s pain management and distress during 
needle-related procedures. Among these, there are sweet-
tasting solutions,32 33 needle-free injection systems,34 35 
vapocoolant sprays36 and distraction.37 38 However, even 
if the efficacy of most of these interventions is well 
demonstrated, their use remains limited in clinical prac-
tice.15 20–22 In fact, these interventions may require 
specific training for healthcare professionals, preparation 
time, or excessive cost, which represent barriers to their 
implementation in the fast-paced environment of the ED 
setting.15 20–22
The limited applicability of both pharmacological and 
non-pharmacological interventions to manage proce-
dural pain and distress in the ED setting demonstrates 
a need for innovation in this domain. The optimal inter-
vention for needle-related procedural pain management 
in the ED would need to be rapid, easy-to-use and without 
side effects. To answer this problem, Dr Amy Baxter, an 
emergency paediatrician and pain researcher in the USA, 
developed a pain blocker device called Buzzy (MMJ Labs, 
Atlanta, Georgia, USA) specifically for pain management 
of children undergoing needle-related procedures. The 
Buzzy is a bee-shaped device combining vibration (body 
of the bee) and cold (removable ice wings).39 The theo-
retical bases explaining the action of the device are the 
Gate Control Theory40 and the diffuse noxious inhibi-
tory control theory, which both involve modulation of 
the transmission of pain.39 Therefore, it is theorised that 
the simultaneous use of vibration and cold would provide 
optimal pain management.
To date, there have been some randomised controlled 
trials that have investigated the efficacy of the Buzzy 
device on pain management in children under-
going needle-related procedures in various medical 
settings.41–49 However, these studies present several 
limitations such as the absence of an active compar-
ator,41 43 44 46–48 the lack of prior power analyses or sample 
size calculation,43 44 lack or unclear allocation conceal-
ment,41–44 47 48 among others. Of those studies, only two 
have been conducted in the ED setting,45 49 and none 
have been done in Canada. The Buzzy device seems to be 
a promising method to reduce and control procedural 
pain in the ED, and it would be interesting to deter-
mine if the it is at least as efficacious as a topical anaes-
thetic for pain management in children and adolescents 
during needle-related procedures.
study objectives
Primary objective
To determine if a device combining cold and vibration 
(Buzzy) is non-inferior (no worse) to a topical anaesthetic 
(liposomal lidocaine 4% cream) for pain management in 
children undergoing needle-related procedures in the 
ED.
Secondary objectives
To determine if, in comparison with a topical anaesthetic 
(liposomal lidocaine 4% cream), the Buzzy device will:
 ► Decrease the level of distress during the needle-re-
lated procedure.
 ► Improve the success of the needle-related procedure 
at first attempt.
 ► Decrease memory of pain 24 hours after the needle-re-
lated procedure.
Other secondary objectives
 ► To determine the occurrence of adverse events in 
each study group.
 ► To evaluate the satisfaction of parents, children and 
nurses regarding the use of the Buzzy device and the 
topical anaesthetic (liposomal lidocaine 4% cream).
MEthod
This study protocol was developed in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials recommendations.50
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trial design and study setting
The study design will be a randomised, controlled, 
non-inferiority trial with two parallel groups and a 1:1 
allocation ratio. This study design is of interest when a 
new intervention seems to present some advantages 
over the reference intervention.51 Considering that the 
Buzzy device seems to be less expensive, faster and easier 
to use than the topical anaesthetic, which is the current 
reference intervention, the choice of a non-inferiority 
trial design was justified. As recommended for a non-in-
feriority trial,51 a study demonstrating the superiority of 
the reference intervention compared with a placebo in 
a similar context should be used as rationale to support 
this study design.51 For this purpose, the study by Taddio 
et al,52 which aimed to determine the efficacy of the lipo-
somal lidocaine 4% cream over a placebo for managing 
pain resulting from venipuncture in children in the ED, 
was used as a reference trial to the current study.
This single-centre study will take place in the ED of 
the CHU Sainte-Justine (Montreal, Quebec, Canada), a 
university paediatric tertiary hospital centre with a census 
of more than 80 000 ED visits per year.
Participants
Participants will be deemed eligible if they meet all of the 
following inclusion criteria: (A) aged between 4 years old 
and 17 years old, (B) presenting to the ED and requiring 
a needle-related procedure (venipuncture or intravenous 
catheter insertion), (C) having the ability to communi-
cate in either French or English and (D) accompanied by 
at least one parent/legal guardian who can understand, 
read and speak French or English. We will exclude chil-
dren with (A) a neurocognitive disability that precludes 
them from assenting and participating to the study, (B) 
an inability to self-report pain, (C) a critical or unstable 
health status (<3 on the Canadian Triage and Acuity 
Scale), (D) a Reynaud’s syndrome or sickle cell disease 
with extreme sensitivity to cold; (E) a break or abrasion 
on the skin where the device would be installed and (F) a 
nerve damage or limited sensation in the extremity where 
the needle-related procedure will be performed. We will 
not exclude children who received analgesics, including 
acetaminophen or ibuprofen, within the 4 hours prior to 
presentation to the ED, but it will be documented.
Interventions
Experimental group: Buzzy device
Participants in the experimental group will receive the 
Buzzy device intervention. The Buzzy is a palm-sized 
device with two components: (1) body of the bee (vibra-
tion) and (2) removable and reusable ice wings (ice). 
The body of the bee is a vibrating motor powered by two 
alkaline AAA batteries, and it lasts for about 20 hours. The 
vibration component is activated by a manual switch on 
the top part of the device. The removable set of wings 
contain a total of 18 g of ice. Each set of ice wings can stay 
frozen for about 10 min at room temperature, and they 
are reusable up to 100 times. Dimensions of the device 
are 8 cm × 5 cm × 2.5 cm. Enrolled children will have the 
opportunity to hold and get familiarised with the Buzzy 
device before the needle-related procedure.
Use and placement of the Buzzy device for the needle-related 
procedure
The research nurse will follow the following steps, as 
recommended by the manufacturer’s (MMJ Labs, Atlanta, 
Georgia, USA): (1) immediately before the needle-re-
lated procedure, a set of ice wings will be retrieved 
directly from the freezer of the ED unit. For optimal effi-
cacy, the wings must be frozen solid; (2) the ice wings will 
be inserted through the elastic bands fixed on the back of 
the Buzzy device; (3) when the staff nurse will be ready to 
clean the site and perform the needle-related procedure, 
the research nurse will install the Buzzy device on the 
child’s arm, above and as close as possible to the insertion 
site (about 3–5 cm) with a reusable tourniquet, and the 
vibration will be then activated. The Buzzy device will be 
installed for about 30 to 60 s prior to the needle-related 
procedure; (4) the device will have to be maintained on 
the child’s arm throughout the procedure, at least until 
the needle is removed; (5) when the procedure is over, 
the two components of the device will be cleaned with 
a disinfectant cleaner based on proprietary accelerated 
hydrogen peroxide (Virox) as per the Infection Preven-
tion and Control guidelines at the study setting; and (6) 
the ice wings will then be put back in the freezer of the 
unit for a subsequent procedure.
Physiological basis of the Buzzy device
The Gate Control Theory40 and the Descending Noxious 
Inhibitory Controls (DNIC) are the theoretical bases 
of the Buzzy device. More specifically, the Gate Control 
Theory stipulates that the vibration component of the 
device blocks the A-delta and C nociceptive fibres by 
stimulating the A-beta non-nociceptive fibres. It activates 
an inhibitory interneuron and results in a reduction of 
the pain signal transmitted to the spinal cord.49 53 The 
cold component (prolonged cold application 30–60 s) 
stimulates the C nociceptive fibres and further blocks 
the A-delta nociceptive pain transmission signal when 
applied close to the needle insertion site.49 The second 
theory behind the Buzzy device is the DNIC. More specif-
ically, intense cold application stimulates the nociceptive 
C fibres and activates a supraspinal modulation which, 
in turn, increases the body’s overall pain threshold and 
therefore produces a generalised hypoalgesia at the inser-
tion site.39 54
Control group: topical anaesthetic (liposomal lidocaine 4% cream).
Participants in the control group will receive an applica-
tion of liposomal lidocaine 4% cream (Maxilene, RGR 
Pharma, LaSalle, Ontario, Canada) over the insertion 
site 30 min before the needle-related procedure. The 
topical anaesthetic cream will be applied by the research 
nurse according to the manufacturer’s recommenda-
tions, and the site will be covered by a Tegaderm dressing 
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(3M Canada Company, London, Ontario, Canada). The 
topical anaesthetic cream and the Tegaderm dressing 
will be removed just before the procedure. This inter-
vention was chosen as an active control intervention as it 
has been shown to be the most effective for pain manage-
ment regarding needle-related procedures,23–26 and it is 
also the standard care currently established in the study 
setting.
The liposomal lidocaine 4% cream has been chosen 
over other topical anaesthetics because of its shorter 
application time (30 min) and its minimal vasoactive 
properties that minimise potential interference with the 
success of the needle-related procedure.52 Currently, the 
gold standard topical anaesthetic cream is a combination 
of lidocaine 2.5% and prilocaine 2.5% cream (Eutectic 
Mixture of Local Anesthetics (EMLA)), but it requires an 
application time of 60 min and it is frequently associated 
with vasoconstriction of blood vessels.55–57 The liposomal 
lidocaine 4% cream has also been chosen due to the 
lower occurrence of rash reactions after its application, 
which is often observed with the amethocaine 4% gel.58 
The ametocaine 4% gel has also been associated with 
vasodilatation and a risk of hypersensitivity with repeated 
use.26
Mechanism of action
The mechanism of action of topical anaesthetics relies 
on the reversible interruption of nerve conduction near 
the application site by inhibiting sodium influx through 
the voltage-gated sodium channels.30 59–61 This inhibi-
tion of sodium influx decreases the ability to generate 
action potentials decreasing or blocking hereby pain 
signals conduction. Following the application, a tempo-
rary loss of sensation in the limited area of application is 
produced.60 61
study proceedings
Recruitment
Eligible participants will be recruited consecutively in the 
ED by two research nurses during study enrolment hours 
(approximately 25 hours/weeks, depending on research 
nurses’ availability). Potentially eligible children will be 
initially assessed on arrival to the ED by triage nurses, staff 
nurses and physicians. Then, when the treating physician 
will have determined that a child will require a venipunc-
ture or a catheter intravenous insertion, the research 
nurse will approach the child and its family to confirm 
study eligibility per the inclusion and exclusion criteria, 
to explain the study in greater details and to answer all 
questions before seeking consent for study participation. 
Informed written consent will be obtained from parents 
or legal guardians and assent will be obtained from chil-
dren over 7 years old. Research nurses will maintain and 
complete a screening and enrolment log to provide a 
comprehensive list of all children who were screened for 
eligibility. Recruited children will be randomly allocated 
to either the experimental (Buzzy device intervention) or 
the control group (liposomal lidocaine 4% cream).
Data collection and outcomes measures
Data collection will start following consent and enrol-
ment. All data will be collected by one of the two research 
nurses using a paper case report form (CRF) developed 
and designed for this study. In addition to the primary 
and secondary outcomes, sociodemographic and clin-
ical data and covariates will be recorded. Data will be 
collected at different end points: before randomisation 
(T-0), 5 min before the needle-related procedure (T-1), 
during the needle-related procedure (T-2), immediately 
after the needle-related procedure (T-3) and 24 hours 
after the needle-related procedure (T-4). Of note, the 
needle-related procedure will be performed by the staff 
nurse and not the research nurse.
Sociodemographic and clinical data
Before randomisation of participants (T-0), sociodemo-
graphic and clinical data will be collected by the research 
nurse. These data will include age, sex, reason for consul-
tation, previous experience(s) of needle-related proce-
dures and analgesia received in the last 4 hours prior the 
procedure. Contact preference and information will also 
be obtained for a follow-up 24 hours after the needle-re-
lated procedure.
Primary outcome measure
The primary outcome will be the mean difference 
in pain scores during the needle-related procedure 
between groups. It will be assessed immediately after the 
first needle-related procedure attempt using the Color 
Analogue Scale (CAS) (T-3). This chosen end point aligns 
with the recommendations on standard assessment of 
post-needle pain.38 The CAS is a self-report paediatric pain 
scale consisting of a plastic ruler with a mechanical slider 
and showing a wedge-shape figure gradually changing in 
colour from white to red. The white end means ‘no pain’ 
and the red end means the ‘worst pain’. The reverse side 
of the scale is numbered from 0 cm to 10 cm with 0.25 
increments, allowing investigators to quantify children’s 
pain.62–64 The CAS has shown excellent psychometric 
properties in children with acute pain in the ED.63 65 The 
child will be shown the side with the wedge-shape figure 
with the mechanical slider in the middle position and will 
be asked to move the slider to the place that corresponds 
to the pain he or she experienced during the needle-re-
late procedure. The meaning of each anchor will also 
be explained to the child prior to using the scale. The 
research nurse will record the corresponding pain score.
Secondary outcomes measures
The secondary outcomes will be the pain intensity during 
the needle-related procedure (T-3), the level of distress 
during the needle-related procedure (T-2, T-3), the 
success of the procedure at first attempt (T-3), the satis-
faction with both interventions (T-3), the occurrence of 
adverse events and the memory of pain 24 hours after the 
needle-related procedure (T-4).
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Pain intensity
Mean difference in procedural pain scores between groups 
will also be assessed using the Faces Pain Scales – Revised 
(FPS-R)66 immediately after the first needle-related proce-
dure attempt (T-3). This self-report pain scale is the revised 
version of the original scale previously developed by Bieri 
et al.67 The FPS-R consists of six faces, and each of them 
represents a greater intensity of pain than the previous one. 
The face on the far-left shows ‘no pain’, and the face on the 
far-right shows ‘very much pain’. On the reversed side of 
the scale, each face is associated with a score ranging from 
0 to 10 (0, 2, 4, 6, 8 and 10).66 This scale is the most recom-
mended to evaluate procedural pain intensity in children, 
particularly in children aged from 4 years old to 12 years 
old.68 Immediately after the procedure, the research nurse 
will ask the child to point the face that shows how much 
pain he or she felt during the needle-related procedure. 
The research nurse will document the pain score associated 
with the face identified by the child.
Level of distress
Mean differences between groups on distress scores 
during the needle-related procedure will be assessed 
using the Procedure Behavior Check List (PBCL)69 (T-2) 
and the Children’s Fear Scale (CFS)70 (T-3). The PBCL is 
an observational scale specifically developed to evaluate 
pain-related fear and anxiety during painful procedures. 
This scale consists of a checklist with eight behavioural 
items: muscle tension, screaming, crying, restraint used, 
pain verbalised, anxiety verbalised, verbal stalling and 
physical resistance. The observer has to rate the inten-
sity of each behaviour on a scale from 1 to 5 (1=very mild 
distress; 5=extremely intense distress).69 The research 
nurse will record the PBCL during the first needle-related 
procedure attempt (T-2). The CFS is a self-report scale 
developed to measure fear of children during painful 
experiences. This scale has five faces with a range of scores 
from 0 to 4 as each face shows an increasing amount of 
being scared moving from left to right.70 Immediately 
after the first needle-related procedure attempt (T-3), the 
child will be asked to choose the face that best shows how 
much he was scared during the procedure. The child will 
be informed that the first face is ‘not scared at all’ and the 
last face is ‘the most scare possible’.70
Success of the procedure at first attempt
The proportion of participants achieving a successful 
procedure at first attempt will be recorded as a binary 
outcome (yes/no) (T-3). If the procedure is not successful 
at first attempt, the research nurse will document the 
number of attempts in the CRF.
Satisfaction
Satisfaction of both interventions will be evaluated using 
three questionnaires tailored for children, parents and 
nurses and including Likert scale questions and dichot-
omised (yes/no) questions. It will be assessed immedi-
ately after the needle-related procedure with parents and 
children (T-3) and when reaching 50% of the targeted 
recruitment for nurses.
Adverse events
The proportion of participants experiencing an adverse 
event will be recorded as a binary outcome (yes/no). An 
adverse event will be defined as an unexpected medical 
occurrence in a participant that may or may not be neces-
sarily causally related to one of the two interventions. 
Adverse events will be recorded after enrolment of the 
participant until hospital discharge.
Memory of pain
The memory of pain will be assessed by comparing pain 
scores between groups 24 hours after the needle-related 
procedure using the FPS-R phrased in terms of recall66 
(T-4). After the needle-related procedure, the research 
nurse will give a paper copy of the FPS-R to each parent or 
legal guardian with the corresponding instructions. They 
will be informed that they will be contacted in the next 
24 hours (±6 hours) by telephone, text message or email, 
depending on their preference. The research nurse will 
then ask the child to point at the face that corresponds 
with how much pain they remember feeling during the 
needle-related procedure at the ED. The child/parent 
will report by telephone, text message or email the chosen 
face (first, second, third, fourth, fifth and sixth) and the 
research nurse will record the answer.
Covariates
Data will be collected from participants and their parents 
for potential covariates. More specifically, preprocedural 
pain (CAS) and preprocedural level of distress (PBCL and 
CFS) will be assessed 5 min before the needle-related 
procedure (T-1). Clinical data will be also recorded during 
the needle-related procedure (T-2), including: type of 
procedure (venipuncture and intravenous catheter inser-
tion), healthcare professional performing the procedure 
(nurse, nursing assistant and phlebotomist), presence of 
parent/legal guardian during the procedure (one parent, 
two parents and none), position of the child during the 
procedure (sitting position, on a parent’s lap, dorsal decu-
bitus and dorsal decubitus against his will), restraints used 
during the procedure (yes/no) and use of other non-phar-
macological interventions during the procedure.
Data management
All data collected with the CRFs will be manually entered 
into an electronic database statistical software, and the 
original CRFs will be kept on file at the participating 
site. Data entry and coding will be performed by the 
same person. A verification will be done by a second 
person to compare with the original CRFs. Each partic-
ipant’s file will be assigned an identification number to 
preserve participant confidentiality. Files will be stored in 
numerical order in a locked file cabinet in the principal 
investigator’s office at the research centre. Files will be 
maintained in storage for a period of minimum 25 years 
 o
n
 6 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023214 on 15 January 2019. Downloaded from 
6 Ballard A, et al. BMJ Open 2019;9:e023214. doi:10.1136/bmjopen-2018-023214
Open access 
after completion of the study, according to Health Canada 
regulations for Health Canada Regulated Clinical Trials.
randomisation and allocation
An independent biostatistician of the Applied Clinical 
Research Unit (Unité de Recherche Clinique Appliquée 
(URCA)) will generate the sequence of randomisation 
as per a computer-generated random listing of interven-
tions applying a permuted block design with random 
blocks stratified by age (4–7 years; 8–12 years; 13–17 
years). The SAS software V.9.3 will be used to generate 
the randomisation list using a prespecified seed to ensure 
reproducibility and proof of random allocation. To 
ensure concealment, the block size will not be disclosed. 
The randomisation sequence will be stored at the URCA 
for the whole duration of the study in order to keep the 
investigators blinded from the study conditions. Enrolled 
participants will be randomly assigned, in a 1:1 allocation 
ratio, to receive either the experimental intervention 
(Buzzy device intervention) or the control intervention 
(liposomal lidocaine 4% cream).
The allocation concealment will be ensured by the 
use of sequentially numbered, opaque and sealed enve-
lopes previously prepared by the URCA. After the 
enrolled participant will have completed all baseline 
measurements, the appropriate numbered envelope will 
be opened by the research nurse. Each envelope will 
contain the randomisation number and the allocated 
intervention.
Due to the major differences between the two inter-
ventions in appearance and timing of application, it will 
not be possible to blind participants, parents, healthcare 
providers and outcome assessors (research nurses) to the 
participant’s allocation.
data analyses
Sample size
The primary aim of this trial is to demonstrate the non-in-
feriority of the Buzzy device compared with a topical anaes-
thetic (liposomal lidocaine 4% cream) for procedural 
pain management during needle-related procedures in 
the ED. To determine the non-inferiority margin, an elec-
tronic survey was sent to 34 paediatric emergency physi-
cians working in ED settings from Quebec and Ontario. 
The following scenario and question were presented: 
‘You are seeing a four year old female requiring an intra-
venous catheter for drug delivery. You are considering 
two interventions for pain management during the 
needle-related procedure: a topical anesthetic applica-
tion (liposomal lidocaine 4% cream) or the Buzzy device. 
You need to assume that both of these interventions have 
the potential for reducing needle-related pain’. ‘What 
is the greatest difference in mean pain reduction, on a 
numerical scale from 0 to 10, between the topical anas-
thetic (liposomal lidocaine 4% cream) and the Buzzy 
device you are willing to accept to routinely adopt the use 
of the Buzzy device over the topical anesthetic (liposomal 
lidocaine 4% cream) for needle-related procedures?’. 
Respondents had to choose a difference ranging from 
0.1 to 1.5 with 0.1 increments. The mean answer was 
0.70; consequently, this value was chosen as the non-in-
feriority margin. Considering that the minimal clinically 
significant difference on the CAS in children with acute 
pain is 1.0 on a scale from 0 to 1071, the choice of a 0.70 
non-inferiority margin is considered conservative and 
insures that a minimally important difference would not 
be missed. Therefore, a sample size of 346 participants 
would be necessary to provide the trial with 90% power 
to show the non-inferiority of the Buzzy device compared 
with a topical anaesthetic at a one-sided alpha level of 
0.025 with the use of a non-inferiority margin of 0.70 for 
the per-procedural pain intensity. We anticipate no loss to 
follow-up considering the short time frame between the 
intervention and the assessment of the primary outcome. 
The sample size was calculated using the G*Power soft-
ware V.3.0.10.
Statistical methods
The primary analysis was designed to test whether the 
Buzzy device is non-inferior to a topical anesthetic (4% 
liposomal lidocaine) for procedural pain management 
during needle-related procedures, as evaluated by calcu-
lating the CI for the mean differences in pain score 
between groups. Non-inferiority would be declared if the 
upper limit of the two-sided 95% CI (1-2α ×100%CI), or 
equivalently, the upper limit of the one-sided 97.5% CI, 
for the between-group difference (experimental group – 
control group) is less than the predetermined non-infe-
riority margin of ∆ 0.70. In this case, the null hypothesis 
of inferiority will be rejected in favour of the alternative 
hypothesis of non-inferiority, and the non-inferiority of 
the Buzzy device over the topical anesthetic (liposomal 
lidocaine 4% cream) will be established. A two-sided 
95% CI will be applied, because it will provide additional 
information if the superiority of the experimental inter-
vention is demonstrated.51 In the case where the non-infe-
riority is met, superiority testing will be performed using 
a two-sided alpha of 0.05 and in looking if the upper limit 
of the CI is less than zero. Non-inferiority analysis will be 
evaluated according to the intention-to-treat principle 
(primary analysis) as well as to the per-protocol principle 
(secondary analysis) to examine for consistency and avoid 
bias.51
The secondary analysis was designed to test the supe-
riority of the Buzzy device over the liposomal lidocaine 
4% cream for secondary outcomes. The Student’s t-test 
will be performed to compare the between-group mean 
differences in preprocedural and procedural distress 
scores. The memory of pain 24 hours after the needle-re-
lated procedure will also be evaluated by the Student’s 
t-test to compare the mean differences in pain scores 
between the experimental and control groups. The 
proportion of participants achieving the success of the 
procedure at first attempt will be calculated in each 
group and compared using the χ2 test. Descriptive statis-
tics will be used to report data collected on satisfaction, 
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as well as sociodemographic and clinical data. Means and 
SD will be reported for continuous variables and propor-
tions will be calculated for categorical and nominal vari-
ables. Potentially relevant preprocedural and procedural 
variables will be included in covariate model (analysis of 
covariance) in an attempt to determine predictors of pain 
scores reduction. All secondary analysis will be carried 
out according to the intention-to-treat principle. For 
superiority testing, a p value <0.05 will be considered as 
indicating statistical significance.
Preplanned subgroups non-inferiority analyses will be 
carried out for the primary outcomes based on age group 
(4–7 years vs 8–12 years vs 13–17 years). As we will not 
have the statistical power in each subgroup to conclude 
to non-inferiority, the results will be considered as explor-
atory and will primarily serve for hypothesis generation 
for future studies. Subgroups superiority analyses will be 
also performed by age group for secondary outcomes. 
Multiple imputation methods and sensitivity analysis will 
be used when possible and appropriate to handle the 
missing data.
No formal interim analysis is planned for this non-infe-
riority trial for different reasons. First, there is no necessity 
to conduct interim analysis for futility reasons in non-in-
feriority trials considering that even if non-inferiority is 
established before the completion of the trial, the data 
collection should be pursued in hope of demonstrating 
superiority.51 Second, considering that we do not expect 
potentially serious adverse events, interim analysis for 
safety reasons and stoppings rules are not required.50 71 
There is also no need to implement a data monitoring 
committee as the known risks are minimal for both inter-
ventions.50 72 73
Patient and public involvement
Patients and public were not involved in the design, 
recruitment and conduct of this study.
dIsCussIon
This study protocol provides the rationale and methods 
associated with a randomised controlled non-inferiority 
trial comparing the Buzzy device to a topical anaesthetic 
with the aim of improving procedural pain and distress 
management in children undergoing needle-related 
procedures. To our knowledge, it will be the first study 
assessing the efficacy of the Buzzy device in Canada in 
any clinical setting. A systematic review currently in 
preparation by our team has identified several limita-
tions in the studies previously conducted on the Buzzy 
device (PROSPERO ID: CRD42017076531). The present 
study is carefully designed to overcome these limitations 
and provide rigorous evidence on its efficacy. The large 
sample size will allow to determine if the Buzzy device is at 
least as efficacious as the liposomal lidocaine 4% cream in 
decreasing procedural pain. Therefore, this study has the 
potential to improve clinical care and outcomes of chil-
dren undergoing needle-related procedures in the ED. 
More specifically, findings from this trial could potentially 
prevent pain and distress experienced by children, as well 
as improve nurses’ pain management practices. In addi-
tion, this study could determine the efficacy of the Buzzy 
device intervention across age ranges and developmental 
differences. If the non-inferiority of the Buzzy is demon-
strated, steps will be taken to eventually obtain a Medical 
Device Licence from Health Canada to make this device 
available in the EDs across Canada.
This study presents some limitations that are important 
to recognise. First, considering the nature and the major 
differences between both interventions, blinding of 
participants and personnel will not be possible. Conse-
quently, they will be aware of the intervention allocation 
once the randomised envelop will be opened. This lack of 
blinding could influence their behaviour and responses 
to outcomes, particularly subjective ones like pain and 
distress creating therefore a potential performance bias.74 
However, the use of an active comparator (anaesthetic) 
will potentially reduce or overcome this bias. Indeed, 
a recent study75 has demonstrated that randomised 
controlled trials using an active comparator reported 
similar expectation ratings from participants between 
groups. Second, it will not be possible to blind the 
secondary outcome assessors (research nurses) as it will 
require observing the participant’s behaviour during the 
procedure. However, the primary outcome assessment 
will be assessed by self-report, which is considered as a 
primary source of evidence for paediatric pain intensity.76 
This could increase the magnitude of the detection bias 
as pain is a subjective measure.77 However, some have 
argued that self-report assessment could be considered as 
equivalent to blinding of outcome assessors considering 
that it is not associated with an overestimated interven-
tion effects, as is the case in psychotherapy meta-anal-
yses.78 79 Third, we decided to exclude children under the 
age of 4 years old as the large majority of blood samples of 
this population are performed via micromethod (blood 
collected in capillary tubes from finger sticks), and the 
use of the Buzzy device is not applicable for these cases. 
The inability of these children to self-report pain was also 
a reason for exclusion.
Finally, although there is an increase in use and devel-
opment of pharmacological and non-pharmacological 
interventions, pain management remains suboptimal. It 
suggests that evidence is not being translated in clinical 
practice or that interventions are underused by health-
care providers.38 80 Therefore, it is important to provide 
healthcare professionals with interventions that are likely 
to be implemented into clinical practice for routine use. 
The Buzzy device is an easy-to-use and fast intervention 
that seems to be a promising option in the ED setting.
EthICs And dIssEMInAtIon
Ethics and safety consideration
This approval covers the protocol, informed consent 
forms and the data collection forms. To date, no 
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important protocol modification has been made after 
the initial ethics approval. As recommended by the Inter-
national Committee of Medical Journal Editors,81 this 
clinical trial was registered in a public trials registry prior 
to the beginning of the recruitment ( ClinicalTrials. gov: 
NCT02616419). An Investigational Testing Authoriza-
tion from the Medical Device Bureau of Health Canada 
was also granted (#272708). Finally, this study will be 
conducted in accordance with the principles of the Decla-
ration of Helsinki82 and all REB policies and guidelines. 
Written informed consent will be obtained from parents 
or legal guardians, and assent will be obtained from chil-
dren over 7 years old. Consent involve a follow-up 24 hours 
after the needle-related procedure. Only the principal 
investigators (AB, CK and SLM) will be given access to 
the complete final data sets. Other investigators will have 
access to the complete final data set if a formal request is 
formulated and approved by the principal investigators.
dissemination
The research protocol has been already presented to 
local clinicians and stakeholders, as well as at national 
and international conferences. Scientific results will be 
disseminated at regional, national and international 
conferences targeting nurses, emergency physicians and 
paediatric researchers. A manuscript will be submitted to 
a high impact peer-reviewed journal.
trial status
Recruitment for this study is ongoing.
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